1.12
0.22 (24.21%)
| Previous Close | 0.902 |
| Open | 0.900 |
| Volume | 2,275,075 |
| Avg. Volume (3M) | 1,047,658 |
| Market Cap | 181,157,760 |
| Price / Book | 0.640 |
| 52 Weeks Range | |
| Earnings Date | 4 Aug 2025 - 18 Aug 2025 |
| Diluted EPS (TTM) | -1.61 |
| Total Debt/Equity (MRQ) | 0.41% |
| Current Ratio (MRQ) | 8.98 |
| Operating Cash Flow (TTM) | -199.43 M |
| Levered Free Cash Flow (TTM) | -108.00 M |
| Return on Assets (TTM) | -48.51% |
| Return on Equity (TTM) | -79.05% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Neumora Therapeutics, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | -0.13 |
|
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 27.57% |
| % Held by Institutions | 60.19% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Softbank Group Corp. | 31 Mar 2025 | 6,541,190 |
| Mic Capital Management Uk Llp | 31 Mar 2025 | 4,460,700 |
| Siren, L.L.C. | 31 Mar 2025 | 4,358,283 |
| Wellcome Trust Ltd (The) As Trustee Of The Wellcome Trust | 31 Mar 2025 | 3,309,123 |
| Iconiq Capital, Llc | 31 Mar 2025 | 2,559,090 |
| Lunate Capital Ltd | 31 Mar 2025 | 2,124,143 |
| Lunate Holding Rsc Ltd | 31 Dec 2024 | 2,124,143 |
| T. Rowe Price Investment Management, Inc. | 31 Mar 2025 | 2,103,029 |
| Johnson & Johnson | 31 Mar 2025 | 1,849,445 |
| 52 Weeks Range | ||
| Median | 5.00 (346.43%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Needham | 13 May 2025 | 5.00 (346.43%) | Buy | 0.679 |
| 10 Apr 2025 | 5.00 (346.43%) | Buy | 0.717 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 09 Jul 2025 | Announcement | Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-861 |
| 07 Jul 2025 | Announcement | Biotech’s Turning Point: 4 Stocks Poised to Ride the 2025 Wave |
| 12 May 2025 | Announcement | Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update |
| 28 Apr 2025 | Announcement | Neumora Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |